[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Health Network, Toronto\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":588},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,254,0,25,[9,46,74,96,119,142,166,189,208,231,251,272,292,317,343,367,390,414,438,462,484,509,527,547,569],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100054072","prospective-reduction-of-transplant-complications-through-enhanced-preservation-therapy-to-prevent-primary-graft-dysfunction-100054072",false,"NCT07230886","Prospective Reduction Of Transplant Complications Through Enhanced Preservation Therapy to Prevent Primary Graft Dysfunction","PROTECT-PGD","Inclusion Criteria:\n\n* Recipient: Adult (\\>17 years old)\n* Donor: Donation after brain death acceptable for transplant as determined by a procuring physician unaware of randomization sequence at the time of acceptance\n\nExclusion Criteria:\n\n* Recipient: Multi-organ transplant recipients; Participating in an interventional study.\n* Donor: Donation after cardiac death; Use of organ care system","ALL","17 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to test the feasibility of the study protocol comparing a novel temperature control system - Xo Port Organ Preservation System - to static ice for heat preservation for Heart Transplant. The main questions of the study are as follows:\n\nDoes the Incidence of severe PGD change within the first 24 hours of heart transplant in patients randomized to the Xo Port Organ Preservation System?\n\nWas there a change in composite efficacy endpoints in participants randomized to the Xo Port Organ Preservation System compared to static ice storage?\n\nWere the feasibility outcomes achieved?\n\nWere there any protocol deviations?\n\nParticipants will:\n\nBe randomized to either the Xo Port Organ Preservation System or static ice storage.\n\nComplete a questionnaire at the time of screening, day 0, 7, and 90 days post transplant.\n\nHave blood drawn - with their standard of care blood draws - after their transplant, the day after, and 7 days post transplant.",[27],"Primary Graft Dysfunction",[27,29,30,31,32],"Transplant","Traferox","Preservation Therapy","X Port Preservation System","RECRUITING","2026-07-09",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2026-04-17",{"date":41,"type":21},"2028-12",{"name":43,"class":44},"University Health Network, Toronto","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":68,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":45},"100053993","well-being-program-for-caregivers-of-patients-with-advanced-cardiac-and-pulmonary-disease-100053993","NCT07685912","Well-being Program for Caregivers of Patients With Advanced Cardiac and Pulmonary Disease","Enhancing Caregiver Wellbeing: The Role of Exercise, Nutrition, and Stress Management for Caregivers of Patients With Advanced Cardiac and Pulmonary Disease","INCLUSION CRITERIA (CAREGIVERS):\n\n* Informal (unpaid) caregivers aged 18 years or older\n* Identified as the primary caregiver of a patient with advanced cardiac or pulmonary disease receiving outpatient palliative care at Toronto General Hospital\n* Ability to provide informed consent\n\nEXCLUSION CRITERIA (CAREGIVERS):\n\n* Presence of any medical condition where moderate physical activity or exercise training would be contraindicated (e.g., unstable cardiovascular disease, recent injury)\n* Significant cognitive impairment or language barrier that would interfere with completing study procedures\n* Lack of access to a phone or internet connection to enable virtual participation\n\nINCLUSION CRITERIA (Patients):\n\n* Aged 18 years or older\n* Diagnosis of advanced cardiac or pulmonary disease and currently receiving outpatient palliative care at Toronto General Hospital\n* Ability to provide informed consent\n\nEXCLUSION CRITERIA (Patients):\n\n* Significant cognitive impairment or language barrier that would interfere with completing study procedures\n* Medical instability that would preclude participation in an interview or completion of questionnaires, as determined by the clinical team\n* Lack of access to a phone or internet connection to enable virtual participation","18 Years",{"count":55,"type":21},80,[24],"Caregivers provide essential support for people living with advanced heart or lung disease, including daily tasks, emotional support, and help with medical care. Although their role is vital, caregivers often experience high levels of stress, fatigue, and challenges with their own health and well-being. This study will test whether it is possible and practical to offer an 8-week wellness program for caregivers that is delivered virtually in their homes. The program includes personalized strategies for physical activity or exercise, healthy eating, and stress management. It will be tailored to the individual needs and schedules of caregivers and supported by regular virtual check-ins with health professionals. We will evaluate whether caregivers find the program acceptable, safe, and feasible to follow. This includes looking at how many caregivers agree to participate, how many complete the program, whether they can follow the activities, and whether they are satisfied with the experience. The study will also explore whether participating in the program may lead to improvements in caregiver quality of life, stress, and confidence in the caregiving role.",[59,60,61],"Caregiver","Cardiac Disease","Pulmonary Diseases",[63,64,65,66],"Exercise","Nutrition","Stress management","Well-being","NOT_YET_RECRUITING",{"date":36,"type":37},{"date":70,"type":21},"2026-07-15",{"date":72,"type":21},"2028-03-30",{"name":43,"class":44},{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":4},"100054042","phase-1-enhancing-icb-efficacy-through-il-1-inhibition-in-tnbc-100054042","NCT07698106","Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC","Rebooting Sensitivity to Checkpoint Blockade Therapy in Triple-Negative Breast Cancer With Isunakinra (RESETT- I)","Inclusion Criteria:\n\n1. Age \\> 18 years\n2. Newly diagnosed, locally advanced, previously untreated and centrally confirmed TNBC, as defined by the most recent American Society of Clinical Oncology (ASCO)\u002FCollege of American Pathologists (CAP) guidelines, and staging per current AJCC staging criteria for breast cancer as assessed by the investigator based on radiological and\u002For clinical assessment:\n\n   Clinical stage T1c\u002FN1-N2, T2-4\u002FN0-2\n3. Provides core needle biopsies consisting of at least 2 separate tumor cores from the primary tumor to the central laboratory\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n5. Demonstrates adequate organ function\n6. Participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study\n\nExclusion Criteria:\n\n1. Male Gender\n2. Luminal A\u002FB and HER2 positive breast cancer\n3. Multifocal early breast cancer\n4. History of invasive malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer\n5. Received prior chemotherapy, targeted therapy, and radiation therapy within the past 12 months\n6. Has received prior therapy with an anti-PD1, anti-PDL1\u002F-PDL2 agent or with an agent directed to another co-inhibitory T-cell receptor\n7. Participated in an interventional clinical study with an investigational compound or device within 4 weeks of randomization for this study\n8. Pre-existing inflammatory arthritis\n9. Has received a live vaccine within 30 days of the first dose of study treatment\n10. Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs)\n11. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (i.e., dosing exceeding 10 mg daily of prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment\n12. Active or uncontrolled Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C\n13. Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis\n14. Has an active infection requiring systemic therapy\n15. Has significant cardiovascular disease\n16. Is pregnant or breastfeeding, or expecting to conceive children within the duration of the study\n17. Has a known history of active tuberculosis (TB, Bacillus Tuberculosis)\n18. Platelets ≤ 100x109\u002FL. ANC ≤ 1.5 x109\u002FL. Hemoglobin ≤ 80 g\u002FL\n19. ECOG≥2\n20. History of stroke or intracranial hemorrhage within 6 months prior to enrollment\n21. Presence of moderate or severe renal function impairment (estimated creatinine clearance \\\u003C60 mL\u002Fmin\u002F1.73m2)\n22. Patients with mild, moderate, or severe hepatic impairment or inadequate liver function (total bilirubin \\> 23 umol\u002FL, serum albumin \\\u003C 35 g\u002FL, INR \\> 1.70)\n23. Known hypersensitivity to E-coli derived proteins, isunakinra or any component of the product",{"count":82,"type":21},60,[84,85],"PHASE1","PHASE2","This study is a phase I\u002FII open-label randomized clinical trial to examine whether administration of isunakinra (EBI-005), a modified recombinant IL1 receptor antagonist, can sensitize human TNBC to the PD1 inhibitor-pembrolizumab-based neoadjuvant chemotherapy (NAC\u002FP) by changing the tumor microenvironment (TME) via reducing the recruitment of immunosuppressive tumorassociated macrophages (TAMs) and increasing activated cytotoxic T-lymphocytes (CTLs).",[88],"Triple-Negative Breast Cancer (TNBC)","2026-07-06",{"date":36,"type":37},{"date":92,"type":21},"2026-08",{"date":94,"type":21},"2034-08",{"name":43,"class":44},{"id":97,"slug":98,"hasResults":12,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},"100550119","extubation-related-complications---the-extube-study-extube-100550119","NCT06442930","EXtubation Related Complications - the EXTUBE Study (EXTUBE)","EXtubation Related Complications - an International Observational Study To Understand the Impact and BEst Practices in the Operating Room and Intensive Care Unit - the EXTUBE Study","EXTUBE","Inclusion Criteria:\n\n* Adult patients (≥18 years old)\n* Undergoing extubation of an endotracheal tube (including index extubation and re-extubations) after general anesthesia in the OR, out of OR anesthesia location or ICU\n* Undergoing extubation during the specified enrollment window\n\nExclusion Criteria:\n\n* Patients will be excluded if the extubation is performed in the context of withdrawal of life support measures,\n* Patients will be excluded if the extubation is performed for tracheostomy decannulation\n\nFor each patient who is not included, reasons for exclusion will be reported.",{"count":105,"type":21},3000,"OBSERVATIONAL","EXTUBE is an international, multicentre, prospective cohort study evaluating the incidence, risk factors, and outcomes of extubation-related complications and describing clinical practices related to extubation after general anesthesia or after critical illness in the operating room (OR), out of OR anesthesia location or intensive care unit (ICU).",[109],"Extubation","2026-06-30",{"date":112,"type":37},"2026-07-02",{"date":114,"type":37},"2025-04-14",{"date":116,"type":21},"2027-12",{"name":43,"class":44},32,{"id":120,"slug":121,"hasResults":12,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":22,"phases":129,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":139,"leadSponsor":141,"locationsCount":45},"100642719","contrast-enhanced-cbct-with-c-arm-hypersight-technology-100642719","NCT07648160","Contrast-enhanced CBCT With C-arm HyperSight Technology","Contrast-enhanced CBCT With C-arm HyperSight Technology: A Feasibility Study","IV-CBCT","Inclusion Criteria:\n\n* Primary biopsy-proven cancer\n* Planning to undergo spatially fractionated radiation therapy\n* Able to provide informed consent\n* Willingness to participate in follow-up\n* ECOG less than or equal to 3\n* Normal creatinine (below 109mmol\u002FL), normal eGF\n\nExclusion Criteria:\n\n* Unable to understand\u002Fprovide consent\n* History of allergic reaction to iodinated IV contrast dye (allergy to MR contrast is not an exclusion criteria)\n* Known renal disease\n* Single kidney\n* Kidney transplant\n* Dialysis\n* Contraindication to MRI",{"count":128,"type":21},20,[24],"This is a single-arm prospective, feasibility study evaluating the intravenous contrast-enhanced cone beam computed tomography (IV CBCT) for image guidance during radiotherapy. Patients treated with SFRT will receive IV-contrast enhanced CT and fMRI before treatment for simulation purposes. Additionally, patients will receive mpMRI just before and IV-contrast enhanced CBCT during their second and last fraction of RT, in addition to the standard of care CBCT that is acquired for daily image-guided patient positioning. Patients will undergo both IV-contrast enhanced CBCT and treatment on the TrueBeam with HyperSight imaging capability. We hypothesize IV contrast enhanced CBCT is feasible, well-tolerated by patients and improves the visibility of the target.",[132],"Advanced Cancer",[134],"IV-contrast-enhanced CT","2026-06-24",{"date":137,"type":37},"2026-06-26",{"date":135,"type":37},{"date":140,"type":21},"2027-07-01",{"name":43,"class":44},{"id":143,"slug":144,"hasResults":12,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":12,"sex":17,"minAge":150,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":22,"phases":152,"briefSummary":153,"conditions":154,"keywords":157,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":4},"100644541","cerebral-autoregulation-and-delirium-study-100644541","NCT07671404","Cerebral Autoregulation and Delirium Study","Reducing Delirium After Cardiac Surgery: Personalized Targeted Blood Pressure Management Strategy Using Cerebral Autoregulation Monitoring: A Pilot Study","AUTO-POD","Inclusion Criteria:\n\n• Consenting patients aged ≥ 60 years undergoing elective complex cardiac surgery (coronary artery bypass grafting plus valve surgery, double-valve surgery, triple-valve surgery, redo operations, or aortic arch surgery), or patients aged ≥ 70 years undergoing isolated coronary artery bypass grafting or single-valve repair\u002Freplacement surgery.\n\nExclusion Criteria:\n\n* Patients with symptomatic cerebrovascular disease.\n* History of delirium.\n* Major neurocognitive impairment (e.g., dementia or Mini-Mental State Examination score \\\u003C 10).\n* Schizophrenia.","60 Years",{"count":82,"type":21},[24],"Approximately one in four elderly patients develops postoperative delirium (POD) after cardiac surgery. POD is associated with prolonged hospitalization, increased mortality, and higher health care costs. While patient-related risk factors are often difficult to modify, surgery- and anesthesia-related factors may be optimized to reduce the incidence of POD. One potentially modifiable factor is intraoperative blood pressure management. Current practice commonly relies on standardized blood pressure targets during cardiac surgery; however, this \"one-size-fits-all\" approach may not account for individual variability in cerebral perfusion requirements. This study proposes a personalized blood pressure management strategy based on real-time monitoring of cerebral autoregulation, with the goal of maintaining optimal cerebral perfusion and protecting the brain from both hypo- and hyper-perfusion",[155,156],"Delirium - Postoperative","Cardiac Surgery",[158],"Cerebral Autoregulation Monitoring","2026-06-22",{"date":137,"type":37},{"date":162,"type":21},"2026-06-01",{"date":164,"type":21},"2028-06-30",{"name":43,"class":44},{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":174,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":22,"phases":177,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":45},"100596689","phase-2-psilocybin-assisted-existential-attachment-and-relational-pearl-therapy-for-caregivers-of-patients-with-advanced-cancer-100596689","NCT07048743","Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Caregivers of Patients With Advanced Cancer","Psilocybin-assisted Existential, Attachment and Relational (PEARL) Therapy for Caregivers of Patients With Advanced Cancer: A Phase II Open-Label Trial","PEARL-C1","Inclusion Criteria:\n\n* 18 years of age or older.\n* Participant must reside in Ontario, Canada.\n* Ability to speak and read English (participant to provide written informed consent and participate in PEARL intervention, as determined by study personnel).\n* No cognitive impairment indicated in medical record or by the primary care physician.\n* Primary or significant caregiver of a patient with advanced cancer enrolled in a companion trial of PEARL for patients with advanced cancer or caregiver of a patient receiving psilocybin-therapy through the Special Access Program (SAP) at University Health Network (UHN); such patients will have been recruited from psychosocial oncology or palliative care clinics at Princess Margaret (study physicians to assess appropriateness of inclusion and whether treatment will support the family system).\n* At least mild anxiety or depression symptoms, defined as a score of \\>5 on the General Anxiety Disorder-7 (GAD-7) or \\>8 on the Patient Health Questionnaire-9 (PHQ-9).\n* Interest in and ability to participate in and complete the PEARL intervention and protocol as outlined.\n* Normal hepatic functioning as determined by prior medical history or\u002Fand screening bloodwork (international normalized ratio \\[INR\\]\\\u003C1.5, aspartate aminotransferase \\[AST\\]\u002Falanine transaminase \\[ALT\\] \\\u003C 2x upper limit of normal, normal range bilirubin, platelets ≥150).\n* Normal renal functioning as determined by prior medical history or\u002Fand screening bloodwork (estimated glomerular filtration rate \\[eGFR\\]\\>45).\n* Participants who are sexually active and could become pregnant or inseminate a partner must be using one method of highly effective contraception (hormonal contraceptives (e.g. combined oral contraceptives, patch, vaginal ring, injectables, and implants); intrauterine device (IUD) or intrauterine system (IUS); vasectomy or tubal ligation). Alternatively, they may use a combination of two or more effective methods of contraception which include male condom, female condom, cervical cap, diaphragm, or contraceptive sponge. These acceptable methods of contraception must be used prior to study entry, during study participation, and for the duration of the study.\n* For participants of child-bearing potential, a negative serum pregnancy test result is required at screening. A urine pregnancy test will be administered on the morning of psilocybin administration for applicable participants. Participants cannot be pregnant or nursing through the duration of the study.\n* If using prescribed medications or other substances, participants must agree to refrain from taking them if instructed by study investigators. These include:\n\n  * not using any non-prescription medication, nutritional supplement, or herbal supplement except when approved by the treatment team (exceptions will be evaluated by the Sponsor-Investigator and will include acetaminophen, non-steroidal anti-inflammatory drugs, and common doses of vitamins and minerals).\n  * not using nicotine for at least 2 hours before psilocybin administration, and not again until approximately 7 hours after psilocybin administration.\n  * consuming approximately the same amount of caffeine-containing beverages (e.g., coffee, tea) that they consumes on a usual morning before arriving at the treatment centre for the psilocybin session day.\n  * not taking any as needed medications on the mornings of psilocybin sessions (with the exception of daily and as needed opioid pain medication).\n  * refraining from using any psychoactive drugs, including alcoholic beverages, within 24 hours of the psilocybin administration.\n* Participants must have a responsible individual to drive them after the dosing session to where they are staying (home, hotel or another location) and to accompany\u002Fattend to them because psilocybin may affect their alertness and concentration on the evening of the dosing session.\n* Participants must agree not to drive or operate machinery for at least 24 hours after dose administration.\n* The therapist involved in the participant's psilocybin dosing session and\u002For the principal investigators will provide their phone number, in advance of the session, to the participant, in case the participant needs to reach them for emergency support in the 24 hours following the psilocybin dosing session. Because the therapists will change from participant to participant, the study team cannot provide the same emergency phone number to every study participant.\n\nExclusion Criteria:\n\n* A history of past intolerability to psilocybin or other psychedelics.\n* Past\u002Fpresent psychiatric diagnoses of bipolar disorder, any psychotic disorder, active substance use disorders, or dementia.\n\n  a. Participants may have current mild alcohol or cannabis use disorder (meets 3 of 11 diagnostic criteria per The Diagnostic and Statistical Manual of Mental Illnesses \\[DSM-5\\]) or moderate alcohol or cannabis use disorder in early remission for the 3 months prior to enrollment (meets 5 of 11 diagnostic criteria per DSM-5).\n* Clinically significant suicidal ideation either currently or within the past 6 months, as judged by study clinicians.\n* Participant under the age of 30 years who has a first degree relative with a primary psychotic disorder.\n* Other personal circumstances or behaviour judged to be incompatible with establishment of rapport or safe exposure to psilocybin.\n* Severe hypertension (defined as systolic blood pressure \\>140 or diastolic pressure \\>90) based on two readings on the same day. If the second reading remains over 140\u002F90 the participant can be brought in for another reading on a different day. Participants can be re-screened for participation once blood pressure is adequately controlled.\n* Hepatic dysfunction (history of cirrhosis and\u002For abnormal parameters \\[INR\\>1.5, elevated AST\u002FALT 2x upper limit, elevated bilirubin, platelets \\\u003C 150\\]) or liver failure, defined as clinical diagnosis of liver fibrosis, cirrhosis of the liver, or advanced liver disease.\n* Cardiovascular conditions including uncontrolled hypertension, heart failure (defined as class IV of the New York Heart Association classification), angina, a clinically significant electrocardiogram \\[ECG\\] abnormality (e.g., atrial fibrillation without rate control, prolonged Corrected QT Interval (QTc) defined as \\> 450ms for males or \\> 470ms for females), transient ischemic attack in the last six months, stroke, peripheral or pulmonary vascular disease (no active claudication).\n* Uncontrolled epilepsy or history of seizures.\n* Diabetes with inability to skip a meal (lunch), requiring administration of medication more than twice daily, or symptomatic hypoglycemia within the prior 30 days.\n* GI bleed in last 6 months.\n* Use of other investigational agents that would be inappropriate to take with psilocybin in the judgement of the investigator, psychoactive prescription medications (e.g., benzodiazepines, lithium, SSRIs), medications having a pharmacological effect on serotonin-2a (5-HT2A) receptors (e.g., olanzapine, mirtazapine, or trazodone), medications that are monoamine oxidase (MAO) inhibitors, any potent metabolic inducers (e.g. rifamycin, rifampin, rifabutin, rifapentine, carbamazepine, phenytoin, phenobarbital, nevirapine, efavirenz, Taxol, dexamethasone, St John's wort) or inhibitors (e.g. HIV protease inhibitors, itraconazole, ketoconazole, erythromycin, clarithromycin, troleandomycin). Note: Inhibitors of UGT1A9 and 1A10 may increase systemic psilocin exposure (i.e., the Cmax and AUC) of psilocin and should be discontinued at least five half-lives prior to the administration of psilocybin. Similarly, aldehyde or alcohol dehydrogenase inhibitors should be discontinued at least 5 half-lives prior to the dose of psilocybin.\n\nIn suitable participants, contraindicated medications may be tapered by a study physician between study enrolment and the psilocybin session when it is deemed safe to do so and in coordination with the prescribing physician. A safe and appropriate tapering regimen will then be developed based on the particular medication, on a case-by-case basis. If taking an MAO inhibitor, the psilocybin session will not be conducted until at least 5 half-lives of the agent have elapsed after the last dose. Participants prescribed opioids will be allowed to take their usual dose regimen for analgesia, including the use of as needed analgesic medications on psilocybin session days.",true,{"count":176,"type":21},15,[85],"The PEARL-C1 trial is a phase II open-label trial. Participants will receive a single high-dose (25 mg) of psilocybin in the context of Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy.",[180],"Caregiver Distress","2026-06-19",{"date":183,"type":37},"2026-06-23",{"date":185,"type":37},"2025-07-16",{"date":187,"type":21},"2027-12-02",{"name":43,"class":44},{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":22,"phases":197,"briefSummary":198,"conditions":199,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":202,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":45},"100578575","phase-2-using-tumor-models-to-determine-treatments-100578575","NCT06813079","Using Tumor Models to Determine Treatments","ADOPT: Adaptive Organoid-Based Precision Therapy Study in Pancreatic Cancer - A Prospective Single-Arm Phase II Trial","Inclusion Criteria:\n\n1. Age 18 years or over\n2. Ability to understand and willing to sign a written informed consent form in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to screening to document their willingness to participate.\n3. Advanced inoperable malignant epithelial pancreatic ductal carcinomas (i.e. primary diagnosis of ductal adenocarcinoma or acinar cell adenocarcinoma, inclusive of all subtypes)\n4. Treatment history meeting one of either:\n\n   1. Stable disease or partial response to FOLFIRINOX (leucovorin calcium\u002Ffolinic acid, fluorouracil, irinotecan hydrochloride, and oxaliplatin) after at least eight cycles of treatment (Cohort B)\n   2. Progression of disease after receiving standard of care chemotherapies (Cohort A).\n\n   i. There is no maximum number of prior lines\n\n   ii. Patients with recurrence within six months of adjuvant-intent chemotherapy will be eligible\n5. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n6. Life Expectancy of greater than 12 weeks\n7. Patients must have acceptable organ function\n8. Patients must have baseline hepatitis B screening. If they have a positive surface antigen the case will discussed with the hepatologist to determine if therapy is indicated. This does not exclude them from study.\n9. Patients must agree to use effective contraceptive methods for the period required by the study.\n10. Patients must have measurable disease\n11. Patient-derived organoid is sensitive to a drug listed for this study, defined by\n\n    1. Consensus agreement in molecular tumor boards, considering the totality of the genomic and organoid data, and the safety profile of the drug, and the clinical situation\n    2. Sensitivity to a drug chosen for the study, based on\n\n    i. IC50 \\\u003C Cmax (maximum plasma concentration) ii. Area under the curve (AUC) \\\u003C 30th percentile of cohort iii. Individual assay fulfills quality control metrics c. Matched clinical scenario (maintenance versus treatment) as outlined in this protocol.\n12. Able to swallow and tolerate oral medication (as applicable)\n\nExclusion Criteria:\n\n1. Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen.\n2. Patient received last dose of chemotherapy within 21 days prior to Cycle 1 Day 1.\n3. Patients with ongoing toxicity ≥ Common Terminology Criteria for Adverse Events (CTCAE) grade 2, other than peripheral neuropathy, related to prior anti-tumour treatment.\n4. Patients with ongoing peripheral neuropathy of ≥ CTCAE grade 3 will be excluded.\n5. Patients concurrently receiving any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement) except for medications that are prescribed for supportive care but may potentially have an anti-cancer effect (e.g. megestrol acetate, bisphosphonates). These medications must have been started ≥ one month prior to enrolment in this study.\n6. Patients with a history of a severe allergic reaction attributed to compounds of similar or biologic composition to the PDO matched drug may be excluded if assessed by the investigator and determined to be unsafe to proceed.\n7. Patients may be on warfarin, low molecular weight heparin or direct factor Xa inhibitors, unless such therapies are prohibited by drug-specific ineligibility criteria.\n8. Patients with known active progressive brain metastases. Patients with previously treated brain metastases are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within one month prior to screening. All patients with previously treated brain metastases must be stable (clinically and radiologically) for at least one month after completion of treatment and either off steroid treatment or only taking physiological doses of steroids prior to the screening step.\n9. Patients with clinically significant pre-existing cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure.\n10. Patients with known left ventricular ejection fraction (LVEF) \\\u003C 40 % as determined by a multigated acquisition (MUGA) scan or echocardiogram.\n11. Patients with stroke (including TIA) or acute myocardial infarction within three months prior to the screening step.\n12. Patients with acute gastrointestinal bleeding within one month prior to the screening step.\n13. Patients with any other clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in the study or which could jeopardize compliance with study requirements including, but not limited to ongoing or active infection, significant uncontrolled hypertension, or severe psychiatric illness\u002Fsocial situations.\n14. Lactating and nursing women.\n15. Patients who do not meet drug-specific eligibility requirements for the drug selected by the treating physician.",{"count":7,"type":21},[85],"The purpose of this study is to see if using Patient Derived Organoids (PDO) to choose a drug for the treatment of pancreatic cancer individually for each patient is useful. The study will look at the number of participants who have a response to their assigned drug.",[200,132,201],"Pancreatic Ductal Carcinoma","Epithelial Tumor",{"date":183,"type":37},{"date":204,"type":37},"2025-04-07",{"date":206,"type":21},"2028-02-17",{"name":43,"class":44},{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":22,"phases":218,"briefSummary":219,"conditions":220,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":224,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":230},"100525590","phase-2-perioperative-vitamin-c-to-reduce-persistent-pain-after-total-knee-arthroplasty-100525590","NCT06123715","Perioperative Vitamin C to Reduce Persistent Pain After Total Knee Arthroplasty","PeRiOperative VItamin C to Reduce perSistent paIn After tOtal kNee Arthroplasty (PROVISION): a Pilot Multicentre Randomized Controlled Trial","PROVISION","Inclusion Criteria:\n\n* Patients \\>18 years old\n* Undergoing a unilateral or bilateral primary total knee arthroplasty for advanced osteoarthritis of the knee\n\nExclusion Criteria:\n\n* TKA for infection (septic joint), fracture, ankylosing spondylitis, lupus, or psoriatic arthritis\n* History of kidney stones, acute or chronic renal failure, hemochromatosis, or glucose-6-phosphate deficiency\n* Unlikely to comply with follow-up (e.g., no fixed address, plans to move out of town)\n* Language difficulties that would impede valid completion of questionnaires\n* Planned staged bilateral TKA\n* Treating surgeon deems patient inappropriate for inclusion in trial\n* Any allergy or sensitivity to milk\n* Pregnant or planning to become pregnant during the study",{"count":217,"type":21},400,[85],"Phase II Multicentre, pilot, parallel-group, blinded, 1:1 randomized controlled trial to determine the feasibility of conducting a larger definitive trail of using vitamin C to reduce persistent pain in patients undergoing total knee arthroplasty surgery.",[221,222,223],"Chronic Pain","Knee Pain Chronic","Post Operative Pain",{"date":183,"type":37},{"date":226,"type":37},"2024-04-16",{"date":228,"type":21},"2027-12-31",{"name":43,"class":44},3,{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":239,"targetDuration":4,"studyType":22,"phases":241,"briefSummary":242,"conditions":243,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":245,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":45},"100520733","phase-2-durvalumab-and-oleclumab-in-resectable-pdac-100520733","NCT06060405","Durvalumab and Oleclumab in Resectable PDAC","Durvalumab and Oleclumab in Resectable PDAC: A Window of Opportunity Study (DORA Trial)","DORA","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Weight ≥ 35 kg\n* Have a life expectancy ≥ 12 weeks\n* Have histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC).\n* Upfront resectable PDAC\n* Have adequate organ and marrow function required for the study\n* Baseline images taken prior to treatment must undergo central review\n* Participants must agree to use study approved methods to prevent pregnancy for study required period\n\nExclusion Criteria:\n\n* Receipt of any conventional or investigational anticancer therapy within 21 days or palliative radiotherapy within 14 days prior to the scheduled first dose of study treatment\n* Prior receipt of any immune-mediated therapy including, but not limited to, other anti CTLA-4, anti-PD-1, anti-PD-L1 including durvalumab antibodies and agents targeting CD73, CD39, or adenosine receptors, excluding therapeutic anticancer vaccines.\n* Concurrent enrolment in another therapeutic clinical study. Enrolment in observational studies will be allowed.\n* Have a history of Grade 3 or greater thromboembolic events in the prior 3 months or thromboembolic event of any grade with ongoing symptoms.\n* Have prior history of myocardial infarction, transient ischemic attack, congestive heart failure ≥ Class 3 based on New York Heart Association Functional Classification or stroke within the past 3 months prior to the scheduled first dose of study treatment.\n* Active or prior documented autoimmune disorders within the past 3 years prior to the scheduled first dose of study treatment with the following exceptions\n\n  * Vitiligo or alopecia\n  * Hypothyroidism not requiring systemic treatment or stable on hormone replacement\n  * Psoriasis not requiring systemic treatment\n  * Any chronic skin condition that does not require systemic therapy\n* Have known active hepatitis infection. Participants with a past or resolved Hepatitis B (HBV) infection are eligible. Participants positive for Hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n* Known to have tested positive for human immunodeficiency virus (HIV) (positive HIV 1\u002F2 antibodies) or active tuberculosis infection\n* Other invasive malignancy within 5 years.\n* Known allergy or hypersensitivity to investigational product formulations.\n* Active grade 3 or greater edema\n* Uncontrolled intercurrent illness\n* Current or prior use of immunosuppressive medication within 14 days prior to the scheduled first dose of study treatment with the following exceptions:\n\n  * Intranasal, topical, inhaled corticosteroids or local steroid injections\n  * Systemic corticosteroids at physiologic doses not to exceed 10 mg\u002Fday of prednisone or equivalent\n  * Steroids as premedication for hypersensitivity reaction\n* Receipt of live, attenuated vaccine within 30 days prior to the scheduled first dose of study treatment\n* Major surgery within 28 days prior to scheduled first dose of study treatment or still recovering from prior surgery. Local are allowed, without needing to wait for the 28 day recovery period.\n* Are pregnant, lactating, or intend to become pregnant during their participation in the study\n* Any condition that, in the opinion of the investigator, would interfere with safe administration or evaluation of the investigational products or interpretation of subject safety or study results",{"count":240,"type":21},22,[85],"This is a multi-site Canadian, window of opportunity study to evaluate the immune activity of durvalumab and oleclumab in resectable pancreatic ductal adenocarcinoma (PDAC) when given prior to surgery.",[244],"Pancreatic Ductal Adenocarcinoma",{"date":183,"type":37},{"date":247,"type":37},"2023-11-29",{"date":249,"type":21},"2026-10-30",{"name":43,"class":44},{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":258,"targetDuration":4,"studyType":22,"phases":260,"briefSummary":261,"conditions":262,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":266,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":45},"100401698","phase-2-study-of-pembrolizumab-with-bendamustine-in-hodgkin-lymphoma-100401698","NCT04510636","Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma","Phase 2 Study Evaluating the Safety and Efficacy of Pembrolizumab (KEytruda) in Combination With Bendamustine (TREanda) in Relapsed\u002FRefractory Hodgkin Lymphoma","Inclusion Criteria:\n\n* Be willing and able to provide written informed consent for the trial and adhere to trial procedures.\n* Be age ≥18 years at the time of signing informed consent.\n* Have histologically confirmed relapsed (disease progression after most recent therapy) or refractory (failure to achieve CR or PR to most recent therapy) classical Hodgkin Lymphoma (RR HL).\n* Must have received at least standard first line chemotherapy for classical Hodgkin Lymphoma, containing an anthracycline, i.e. ABVD or BEACOPP.\n* Must have failed or declined autologous stem cell transplantation (ASCT), or not be a candidate for ASCT (as per institutional criteria).\n* May have received prior therapy with pembrolizumab (or an equivalent checkpoint inhibitor or anti-PD-L1 antibody), but not in combination with bendamustine.\n* May have received a prior autologous stem cell transplant but must be at least ≥100 days post-auto-transplant, and all transplant- related adverse events must have resolved to a grade 1 or less, and patients are not on immunosuppression, and meet all other eligibility criteria.\n* Must have measurable or evaluable disease, as defined as at least one lesion that can be accurately measured in at least 2 dimensions by CT\u002FPET scan. The minimum measurement must be \\>15 mm in the longest dimension or \\>10 mm in the short axis. Baseline FDG-PET scan must be positive (i.e. FDG-avid HL). Measurements must be done within 28 days prior to trial inclusion..\n* Must have Eastern Cooperative Group (ECOG) performance status 0-1.\n* Must have an estimated life expectancy of greater than 90 days.\n* Demonstrate adequate organ and bone marrow function. All screening laboratory tests should be performed within 7 days of treatment initiation.\n* If FOCBP (defined as any female who has experienced menarche and who has not undergone surgical sterilization (i.e. hysterectomy or bilateral oophorectomy) and is not postmenopausal (menopause is defined as 12 months of amenorrhea in a woman over the age of 45 years in the absence of other biological or physiological causes), eligible patients must have a negative pregnancy test within 72 hours prior to the first dose of study treatment. If the urine test is positive, a serum pregnancy test will be required.\n* All participants must be willing to use adequate contraception for the duration of treatment with study drugs and continue for 120 days after the last dose of study drug.\n* If male, and sexually active with FOCBP, must agree to use adequate contraception for the duration of treatment with study drugs and continue for 120 days after the last dose of study drug.\n* Azoospermic male, or male and FOCBP who are continuously not heterosexually active, are exempt from contraceptive requirements. However, they must still undergo pregnancy testing as described.\n* Must be available for treatment, assessment and follow-up.\n\nExclusion Criteria:\n\n* There is known severe (≥ Grade 3) hypersensitivity to pembrolizumab or bendamustine.\n* Patient receiving any other investigational agents, or on current treatment for RR HL, or has participated in a study of an investigational agent and has received study therapy or used an investigational device within 4 weeks of the first dose of treatment.\n\nNote: Subjects who have entered the follow-up phase of an investigational trial may participate as long as it has been 4 weeks since the last dose of the previous investigational agent.\n\n* Patient is receiving any other, non-investigational, chemotherapy, radiotherapy, small molecule, or biologic agent within 4 weeks of the first dose of treatment, or who has not recovered (i.e., ≤Grade 1 or to baseline) from AEs due to a previously administered agent.\n* Patient has had a prior monoclonal antibody within 4 weeks prior to first dose of therapy in the study, or who has not recovered from adverse events due to agents administered more than 4 weeks earlier.\n* Patient has received pembrolizumab, or another anti-PD1, or anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4, or anti-OX-40 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways, with disease progression whilst on therapy, or within 3 months of completion of this line of therapy, without intervening systemic therapy (including chemotherapy, antibody drug conjugates or other targeted agents).\n* Patient has received prior treatment with bendamustine, either as monotherapy or as part of a combination regimen.\n* Patient has undergone prior allogeneic hematopoietic stem cell transplant.\n* Patient has another concurrent active malignancy (excluding non-melanoma skin cancer or carcinoma in situ of the cervix that has undergone potentially curative therapy), and must be disease-free and off treatment for \\> 3 years.\n* Patient has known active central nervous system or meningeal disease.\n* Patients with active or past documented autoimmune disease that has required treatment in the past 2 years.\n* Patient is receiving systemic steroid therapy at a dose of \\> 10 mg\u002Fday of prednisone (or equivalent) for 7 days prior to day 1 of study treatment.\n* Has an uncontrolled co-existing illness, including but not limited to: ongoing or active infection requiring systemic therapy; systemic congestive heart failure Class III or IV by NYHA criteria; unstable angina pectoris or cardiac arrhythmia; in patients status post allogeneic transplantation uncontrolled GVHD.\n* Patient has a history of (non-infectious) pneumonitis that has required steroid treatment, or concurrent active pneumonitis.\n* Patient is pregnant, or nursing, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of pembrolizumab and\u002For bendamustine.\n* Has a known history of Human Immunodeficiency Virus (HIV), active tuberculosis (TB, Mycobacterium tuberculosis), or active hepatitis B or hepatitis C.\n* Patient has received a live vaccine within 30 days prior to first dose of study drugs.\n* Patient is eligible for autologous or allogeneic stem cell transplant, unless patient has declined this, therefore rendering themselves ineligible for stem cell transplantation.",{"count":259,"type":21},40,[85],"This is a phase 2 open-label study to test the safety and effectiveness of combining pembrolizumab and bendamustine in patients with relapsed (cancer that has come back or started getting worse) or refractory (cancer that is not responding or has stopped responding to treatment) Hodgkin lymphoma.",[263,264,265],"Classical Hodgkin Lymphoma","Relapsed Cancer","Refractory Cancer",{"date":183,"type":37},{"date":268,"type":37},"2021-12-20",{"date":270,"type":21},"2026-11-01",{"name":43,"class":44},{"id":273,"slug":274,"hasResults":12,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":22,"phases":280,"briefSummary":281,"conditions":282,"keywords":284,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":286,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":45},"100348562","circulating-tumor-dna-in-soft-tissue-sarcoma-100348562","NCT03818412","Circulating Tumor DNA in Soft Tissue Sarcoma","Circulating Tumor DNA Detection in Soft Tissue Sarcoma (DNA-TSAR)","Inclusion Criteria:\n\n* Patients must have histologically confirmed high-risk extremity or retroperitoneal liposarcoma, leiomyosarcoma and undifferentiated pleomorphic sarcoma.\n* Patients must have archival tissue from the diagnostic biopsy available.\n* Deemed appropriate for preoperative or postoperative radiotherapy and curative surgery following patient assessment by radiation oncologist and surgical oncologist.\n* Age 18 years or older.\n* Eastern Cooperative Group (ECOG) performance status ≤ 2\n* Ability to understand and willing to sign a written informed consent document and comply with study requirements.\n\nExclusion Criteria:\n\n* Patients with benign histology\n* Patients with prior malignancy within previous 5 years or concurrent malignancy other than adequately treated basal cell carcinoma of skin or carcinoma in-situ of cervix.\n* Patients with planned neo-adjuvant chemotherapy.\n* Patients with regional nodal disease or unequivocal metastases\n* Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.",{"count":259,"type":21},[24],"This research study will collect blood and tumor tissue samples from patients with soft tissue sarcoma to look at circulating tumor deoxyribonucleic acid (DNA). When tumor cells are damaged or die, DNA from the tumor cells are released into the blood stream as the cells break down. This is called circulating tumor DNA. Circulating tumor DNA is an important biomarker that may be used in cancer detection, prediction of treatment response, and disease monitoring.",[283],"Soft Tissue Sarcoma",[285],"Circulating tumor DNA",{"date":183,"type":37},{"date":288,"type":37},"2019-01-17",{"date":290,"type":21},"2026-12-17",{"name":43,"class":44},{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":298,"eligibilityCriteria":299,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":300,"targetDuration":4,"studyType":22,"phases":302,"briefSummary":303,"conditions":304,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":45},"100644113","phase-1-samuraciclib-in-combination-with-gemcitabinenab-paclitaxel-in-patients-with-metastatic-basal-like-pancreatic-cancer-100644113","NCT07665684","Samuraciclib in Combination With Gemcitabine\u002FNab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer","Phase Ib\u002FII Study of Samuraciclib in Combination With Gemcitabine\u002FNab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer","SONIC","Inclusion Criteria:\n\n1. Age ≥ 18 years at the time of screening.\n2. Written informed consent and any locally required authorization (eg, data privacy) obtained from the patient prior to performing any protocol-related procedures, including screening evaluations.\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at the time of screening.\n4. Must have life expectancy ≥ 12 weeks at the time of screening.\n5. Histologically or cytologically confirmed PDAC: Eligible histological variants include: mucinous adenocarcinoma, independent cell adenocarcinoma, adenosquamous carcinoma, adenocarcinoma not otherwise specified (NOS).\n6. Dose Escalation: All patients with metastatic PDAC will be permitted to enrol.\n7. Dose Expansion: Patients with metastatic basal-like PDAC will be permitted to enrol, based on the PurIST assay or by transcriptomic sequencing. Patients will be permitted to start no more than one cycle of gemcitabine\u002Fnab-paclitaxel while waiting for transcriptional subtype results in the dose expansion cohort.\n8. Radiographic evidence of metastatic disease that is measurable per RECIST 1.1.\n9. Adequate organ and marrow function within 28 days prior to dosing on Day 1.\n10. Adequate liver function (AST ≤2.5 times the institutional upper limit of normal, total bilirubin ≤2 times the institutional upper limit of normal) at the baseline visit. Patients are permitted to enroll with biliary obstruction, as long as they undergo appropriate biliary decompression (can be done at the same time as endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB)) and hepatic parameters have improved at time of baseline visit.\n11. Patients must have either de novo metastatic disease or recurrence \\>6 months after completion of neoadjuvant or adjuvant intent systemic therapy.\n12. Patients must have recovered to ≤ Grade 1 in terms of toxicity from prior treatments at the time of enrollment (excluding neuropathy which can be ≤ Grade 2, and alopecia)\n13. Patients must be able to take oral medications.\n14. Females of childbearing potential who are sexually active with a nonsterilized male partner must use at least one highly effective method of contraception from screening to 180 days after the final dose of study treatment. It is strongly recommended for the male partner of a female patient to also use male condom plus spermicide throughout this period. Cessation of contraception after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception.\n15. Nonsterilized male patients who are sexually active with a female partner of childbearing potential must use a male condom with spermicide from screening to 180 days after receipt of the final dose of study treatment. It is strongly recommended for the female partner of a male patient to also use a highly effective method of contraception throughout this period. In addition, male patients must refrain from sperm donation while on study and for 180 days after the final dose of study treatment.\n\nExclusion Criteria:\n\n1. Participants receiving any other study agents concurrently with the study drugs.\n2. Known homologous recombination deficient pancreatic cancer, including germline or somatic BRCA1\u002F2 or PALB2 mutations\n3. Concurrent enrolment in another therapeutic clinical study. Enrolment in observational or supportive care studies will be allowed.\n4. History of a malabsorption syndrome or uncontrolled nausea, vomiting, or diarrhea that may interfere with the absorption of oral study medication in the opinion of the investigator.\n5. Patients with a history of Grade 3 or greater thromboembolic events in the prior 3 months to the scheduled first dose of study treatment or thromboembolic event of any grade with ongoing symptoms.\n6. Patients with prior history of myocardial infarction, transient ischemic attack, congestive heart failure ≥ Class 3 based on New York Heart Association Functional Classification or stroke within the past 3 months prior to the scheduled first dose of study treatment.\n7. Known active hepatitis infection, positive hepatitis C virus (HCV) antibody, hepatitis B virus (HBV) surface antigen (HBsAg) or HBV core antibody (anti-HBc), at screening. Participants with a past or resolved HBV infection (defined as the presence of anti HBc and absence of HBsAg) are eligible. Participants positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n8. Known to have tested positive for human immunodeficiency virus (HIV) (positive HIV 1\u002F2 antibodies) or active tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice).\n9. Other invasive malignancy within 2 years. Non-invasive malignancies (ie, cervical carcinoma in situ, in situ prostate cancer, non-melanomatous carcinoma of the skin, ductal carcinoma in situ of the breast that has been surgically cured) are excluded from this definition. Malignancy treated with curative intent and with no known active disease ≥2 years before the first dose of study treatment and of low potential risk for recurrence are permitted.\n10. Known allergy or hypersensitivity to investigational product formulations.\n11. Active grade 3 or greater edema (eg, peripheral, pulmonary).\n12. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.\n13. Participants with known untreated brain metastases are excluded. Patients with a history of brain metastases are permitted to enroll if they have been treated and have been stable for a minimum of one month on imaging. Participants must be off all corticosteroids at the time of enrolment.\n14. Major surgery (as defined by the investigator) within 28 days prior to scheduled first dose of study treatment or still recovering from prior surgery. Local procedures (eg, placement of a systemic port, core needle biopsy, etc) are allowed, without needing to wait for the 28 day recovery period.\n15. Females who are pregnant, lactating, or intend to become pregnant during their participation in the study.\n16. Any condition that, in the opinion of the investigator, would interfere with safe administration or evaluation of the investigational products or interpretation of patient safety or study results.",{"count":301,"type":21},67,[84,85],"The purpose of this study is to find the highest dose of a drug, samuraciclib, that can be given with standard of care chemotherapy (gemcitabine and nab-paclitaxel) without causing very severe side effects. This is done by starting at a dose lower than the one that is used when samuraciclib is taken by itself without chemotherapy. The main question it aims to answer is:\n\n• For patients with newly diagnosed metastatic pancreatic cancer, what is the safety and tolerability of samuraciclib with gemcitabine\u002Fnab-paclitaxel?\n\nParticipants will:\n\n* Undergo a tumor biopsy.\n* Be treated with samuraciclib in combination with their standard of care chemotherapy (gemcitabine\u002Fnab-paclitaxel).\n* Donate research blood samples.",[305,306,307,308,309],"Pancreas Ductal Adenocarcinoma","Pancreas Cancer, Metastatic","Pancreatic Adenocarcinoma Metastatic","Adenosquamous Carcinoma of the Pancreas","Mucinous Adenocarcinoma","2026-06-18",{"date":135,"type":37},{"date":313,"type":21},"2026-07",{"date":315,"type":21},"2030-05",{"name":43,"class":44},{"id":318,"slug":319,"hasResults":12,"nctId":320,"briefTitle":321,"officialTitle":322,"acronym":323,"eligibilityCriteria":324,"healthyVolunteers":12,"sex":17,"minAge":325,"maxAge":326,"enrollmentInfo":327,"targetDuration":4,"studyType":22,"phases":329,"briefSummary":330,"conditions":331,"keywords":334,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":230},"100583599","cannabinoids-for-osteoarthritis-pain-effectiveness-trial-100583599","NCT06878417","Cannabinoids for Osteoarthritis Pain Effectiveness Trial","The Effectiveness of Oral Cannabis Extracts for Osteoarthritic Pain: an Internal Pilot, Placebo Controlled, Blinded Randomized Trial","COPE","Inclusion Criteria:\n\n1. Age 40-80 years\n2. Diagnosed with hip and\u002For knee osteoarthritis as per the American College of Rheumatology criteria\n3. Experiencing moderate to severe pain interference as indicated by a PROMIS-PI SF-6a T-score ≥ 60\n4. Have not initiated any new analgesics or osteoarthritis treatments in the previous 4 weeks\n5. Able to self-report, understand and read English or French\n\nExclusion Criteria:\n\n1. Hip or knee surgery planned in the coming 4 months,\n2. Injection into the affected joint(s) within the past 3 months (e.g., cortisone, plasma-rich protein, etc.),\n3. Planned injection into the affected joint(s) during trial period,\n4. Inflammatory arthritis (e.g., rheumatoid arthritis, Psoriatic arthritis, gout, etc.),\n5. Contraindications to taking cannabis\u002Fcannabinoids,\n6. Used nabilone or nabiximols in the last 30 days,\n7. Used cannabis (medical or recreational) in the last 30 days (to allow sufficient washout),\n8. A history of diagnosed cannabis use disorder or dependence,\n9. Active substance use disorder,\n10. Current DSM-V diagnosis of bipolar disorder, major depression, or psychosis,\n11. An uncontrolled medical or major psychiatric disorder,\n12. Currently on warfarin,\n13. Known pregnancy or currently breastfeeding,\n14. Men and women planning a pregnancy during the study or in the 12 weeks after stopping IPs\n15. No fixed address or a plan to change addresses in the coming 4 months,\n16. Known or suspected allergy to palm\u002Fcoconut oil","40 Years","80 Years",{"count":328,"type":21},100,[24],"This study aims to investigate whether oral cannabis extracts can effectively manage pain caused by osteoarthritis (OA), a common joint condition affecting one in seven Canadians. Current OA treatments often have limited effectiveness and may cause side effects. As a result, many individuals with OA turn to medical cannabis for pain relief, despite limited scientific evidence supporting its efficacy.\n\nThe goal of this study is to assess the feasibility of a larger trial evaluating the effects of two cannabis compounds-CBD and THC-compared to a placebo (a look-alike substance containing no active drug) on pain interference in patients with hip and\u002For knee osteoarthritis.\n\nParticipants will:\n\n* Take either CBD, THC, or a placebo capsule daily for 8 weeks\n* Complete follow-ups remotely, with no in-person clinic visits required\n* Maintain a diary tracking their study drug usage and any additional pain medications",[332,333],"Osteoarthritis of Knee","Osteoarthritis Hip",[335],"Medical Cannabis","2026-06-17",{"date":159,"type":37},{"date":339,"type":37},"2026-01-29",{"date":341,"type":21},"2027-02-28",{"name":43,"class":44},{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":4,"eligibilityCriteria":349,"healthyVolunteers":12,"sex":17,"minAge":325,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":22,"phases":351,"briefSummary":352,"conditions":353,"keywords":355,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":361,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":45},"100535529","charm-copd-program-of-care-100535529","NCT06253013","CHARM-COPD Program of Care","A Program of Care in Chronic Obstructive Pulmonary Disease Involving Virtual Pulmonary Rehabilitation, Integrated Care and Remote Clinical Monitoring After Discharge From a Recent Exacerbation: Mixed-Methods Study on Feasibility","Inclusion Criteria:\n\n* Referred to either Virtual Pulmonary Rehabilitation or Remote Clinical Monitoring at Toronto Grace Health Centre after discharge from UHN hospital with an AECOPD as defined by the clinical team\n\nExclusion Criteria:\n\n* Pulmonary condition other than COPD as the main respiratory disease such as bronchiectasis or asthma\n* Projected life expectancy ≤ 2 months , as determined by the clinical team\n* Significant cognitive impairment and absence\u002Finability of a family caregiver to consent and to follow study processes",{"count":328,"type":21},[24],"The investigators' goal for this project is to evaluate the feasibility, acceptability, and actual usage of a program of care for patients with COPD recently discharged after an acute exacerbation. The program of care includes virtual pulmonary rehabilitation, integrated care, and remote clinical monitoring.",[354],"Chronic Obstructive Pulmonary Disease",[356,357,358,359,360],"Remote Clinical Monitoring","COPD","Wearables","Digital Health","Self-management",{"date":159,"type":37},{"date":363,"type":37},"2023-09-15",{"date":365,"type":21},"2027-06",{"name":43,"class":44},{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":371,"acronym":4,"eligibilityCriteria":372,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":373,"enrollmentInfo":374,"targetDuration":4,"studyType":22,"phases":376,"briefSummary":378,"conditions":379,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":384,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":388,"locationsCount":389},"100429589","phase-3-prevention-of-persistent-pain-with-lidocaine-infusions-in-breast-cancer-surgery-plan-100429589","NCT04874038","Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN)","Inclusion Criteria:\n\n1. Age ≥18 years old\n2. Undergoing a unilateral or bilateral lumpectomy or mastectomy, inclusive of all pathologies, including prophylactic surgery (e.g., family history or BRCA gene mutation)\n\nExclusion Criteria:\n\n1. Previous breast surgery within 6 months of index surgery\n2. Undergoing any autologous flap procedure during index surgery\n3. Presence known chronic pain disorder involving surgical site or ipsilateral chest wall, shoulder, or arm during the 3-months prior to index surgery\n4. Documented hypersensitivity or allergy to lidocaine\n5. Surgery not planned to be performed under general anesthesia and\u002For planned use of regional or neuraxial anesthetic techniques before surgery (i.e., epidural, paravertebral, serratus plane block, pectoralis or modified pectoralis block)\n6. History of ventricular tachycardia, ventricular fibrillation, or atrioventricular block without a pacemaker\n7. Known cirrhotic liver disease\n8. Pregnant\n9. Unlikely to comply with follow-up (e.g. no fixed address, language difficulties that would impede valid completion of questionnaires, plans to move out of town)","100 Years",{"count":375,"type":21},1602,[377],"PHASE3","Phase III, international multicentre, parallel group, blinded, 1:1 randomized controlled trial to determine the effect of an intraoperative intravenous lidocaine infusion on reducing the development of persistent pain 3-months after breast cancer surgery.",[380,381,382,383],"Post-mastectomy Pain Syndrome","Breast Cancer","Pain, Postoperative","Pain, Chronic",{"date":159,"type":37},{"date":386,"type":37},"2021-09-22",{"date":270,"type":21},{"name":43,"class":44},17,{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":397,"minAge":53,"maxAge":4,"enrollmentInfo":398,"targetDuration":4,"studyType":22,"phases":400,"briefSummary":401,"conditions":402,"keywords":404,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":408,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":45},"100126437","high-dose-rate-brachytherapy-100126437","NCT00913939","High-Dose-Rate Brachytherapy","MRI-Guided HDR Brachytherapy for Prostate Cancer","Inclusion Criteria:\n\n* Prior enrollment of UHN 05-0641-C or UHN 12-5015-C (Arm 1)\n* Histological evidence of recurrent prostate adenocarcinoma (Arm 1)\n* PSA doubling time \\> 6 months (Arm 1)\n* Intermediate and High-risk localized prostate cancer (\\>T1 or PSA\\>10 or Gleason \\> 6) (Arm 2)\n* Planned for EBRT + HDR boost (+\u002F- hormone therapy) (Arm 2)\n* ECOG 0 or 1\n* Age \\> 18 years\n* Informed consent: All patients must sign a document of informed consent indicating their understanding of the investigational nature and risks of the study before any protocol related studies are performed.\n\nExclusion Criteria:\n\n* Radiological evidence of regional or distant metastases\n* Contraindications to MRI (Patient weight as per MRI Technologist's discretion, Patients with pacemakers, cerebral aneurysm clips, shrapnel injury, or implantable electronic devices not compatible with MRI)\n* Bleeding diathesis and anti-coagulative therapy that cannot be temporarily ceased during brachytherapy\n* Previous prostate brachytherapy\n* Active hormonal therapy at time of brachytherapy (Arm 1)\n* Previous pelvic radiotherapy (Arm 2)\n* Contraindications to endorectal coil, surgically absent rectum, severe hemorrhoids or colorectal surgery.\n* Latex Allergy\n* Contraindications to conscious sedation, local anesthesia, or spinal\u002Fepidural anesthesia.\n* IPSS \\>18\n* Large TURP defect\n* TURP within the past 6 months\n* Prostate gland size \\>80cc (Arm 2, whole gland HDR patients only)\n* History of Ulcerative Colitis and SLE (except for patients where the clinician determines benefit outweighs the risk of radiation)\n* Other medical conditions deemed by the PI to make patient ineligible for MRI-guided Prostate HDR brachytherapy.","MALE",{"count":399,"type":21},500,[24],"This pilot study initiates a research program testing the early technical and clinical performance of a novel procedure for MRI-guided high-dose-rate (HDR) prostate brachytherapy. Testing will proceed in two cohorts of patients. In Arm 1, patients with locally recurrent prostate cancer after radiotherapy will receive tumor-targeted salvage HDR brachytherapy. Arm 1 of the study will be coordinated and closely integrated with a separate concurrent study of MRI-guided prostate biopsy, which will be performed prior to accrual to Arm 1 of this trial (UHN 05-0641-C). In arm 2, patients with locally advanced prostate cancer will receive a boost of prostate-targeted HDR brachytherapy during external beam radiotherapy.\n\nThis technique will be prospectively evaluated in up to 500 patients. Preliminary data acquired in this pilot study will determine the technical limits of MRI guided HDR brachytherapy and will be critical for the judicious conduct of a subsequent phase II clinical trial.\n\nThis proposal is innovative in two fundamental ways: MRI-guidance, and specific tumor targeting for HDR brachytherapy. Successful completion of this study will further individualize local therapy, not only for the benefit of the proportion of cancer patients for whom initial radiotherapeutic interventions have failed, but also provide valuable technical and clinical validation that these novel image-guided (IG) approaches are clinically feasible and could be applied more broadly in prostate cancer therapy.",[403],"Patients With Prostate Cancer",[405,406,407],"Prostate Cancer","HDR Brachytherapy","Prostate Brachytherapy",{"date":159,"type":37},{"date":410,"type":4},"2009-05",{"date":412,"type":21},"2027-05",{"name":43,"class":44},{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":420,"eligibilityCriteria":421,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":422,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":423,"conditions":424,"keywords":428,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":45},"100632836","heart-rate-variability-as-a-marker-for-titrating-high-flow-nasal-cannula-therapy-100632836","NCT07518862","Heart Rate VAriability as a MaRker for tItrATing hIgh flOw Nasal Cannula Therapy","Heart Rate Variability as a Marker for Titrating High Flow Nasal Cannula Therapy in Patients With Respiratory Failure","VARIATION","Inclusion Criteria:\n\n* Age \\> 18\n* Currently receiving High-Flow Nasal Cannula Therapy\n\nExclusion Criteria:\n\n* FiO2 ≥ 90%\n* Pacemaker rhythm or presence of atrial fibrillation\n* Post-cardiac surgery patients\n* Contra-indications to electrical impedance tomography (EIT) and\u002For electrocardiogram (ECG) (active implantable medical device, burns, thoracic wounds limiting electrode placement)\n* Non-English-speaking",{"count":128,"type":21},"High-flow nasal cannula is a type of non-invasive respiratory support that helps patients breathe more comfortably. Because the flow is high, it can deliver more oxygen to the lungs and make breathing easier by reducing the effort needed to breathe. However, the best strategy to determine the best oxygen flow rate remains uncertain. Reducing flow rates prematurely can increase work of breathing and prolong ICU stay, while unnecessary prolongation can increase costs. Currently, evidence to guide titration is limited.\n\nHeart rate variability is the natural variation in the time between each heartbeat. Heart rate variability reflects the level of autonomic nervous system activity in response to stress. The autonomic nervous system is the part of the nervous system that automatically controls how heart rate speeds up and slows down. When heart rate variability is higher, it indicates that the system is able to adjust to changes in the body, including stress. However, when heart rate variability is low, it indicates that the system is constrained and in a state of stress.\n\nThe VARIATION study is designed to characterize how heart rate variability goal of this observational study is to learn whether heart rate variability can serve as a marker of the appropriateness of high flow nasal cannula flow support during flow titration in patients with respiratory failure. The main question it aims to answer is:\n\nDoes heart rate variability change before other conventional respiratory signs when there are changes in respiratory function due to inadequate flow rate?\n\nParticipants already on high flow nasal cannula as part of their regular medical care will:\n\n1. Undergo a stepwise decrease in high flow nasal cannula flow rate.\n2. Be recorded continuously with electrocardiogram and electrical impedance tomography.",[425,426,427],"Respiratory Failure","Heart Rate Variability (HRV)","High Flow Nasal Cannula",[429,430],"Electrocardiogram (ECG)","Electrical Impedance Tomography (EIT)","2026-06-16",{"date":310,"type":37},{"date":434,"type":37},"2026-05-26",{"date":436,"type":21},"2026-12",{"name":43,"class":44},{"id":439,"slug":440,"hasResults":12,"nctId":441,"briefTitle":442,"officialTitle":443,"acronym":444,"eligibilityCriteria":445,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":446,"targetDuration":4,"studyType":22,"phases":448,"briefSummary":449,"conditions":450,"keywords":453,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":456,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":45},"100564813","phase-2-pneumonitis-prevention-protocol-using-pentoxifylline-and--tocopherol-in-stage-iii-non-small-cell-lung-cancer-patients-undergoing-chemoradiation-100564813","NCT06634056","Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation","Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol in Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation","P4-PACIFIC","Inclusion Criteria:\n\n* Female and\u002For male aged ≥ 18 years.\n* Histologically confirmed diagnosis of stage III NSCLC, planned for treatment with concurrent chemoradiation and consolidation immune checkpoint inhibitor as per standard of care with no medical contraindications to therapy.\n* Patients with ECOG performance status 0-2 within 4 weeks of randomization.\n* Adequate liver function (no evidence of Child-Pugh class C disease or cirrhosis) as per blood work done within 30 days of registration.\n* Adequate kidney function (Creatinine clearance \\> 50 mL\u002Fmin) as per blood work done within 30 days of registration.\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational product during the last 6 months prior to registration.\n* Patients who will have surgery as part of curative treatment.\n* Previous radiotherapy to intended treatment volumes in the thorax.\n* Active pregnancy.\n* Life expectancy of less than 12 months.\n* Hypersensitivity to Pentoxifylline or other xanthines such as caffeine, theophylline and theobromine or tocopherol (vitamin E).\n* Participant has a history of acute (within 3 months) myocardial infarction, coronary artery disease, or cardiac arrhythmias.\n* Ongoing hemorrhage or major bleeding risk. Patients on antiplatelets agents and anticoagulants (Aspirin, Clopidogrel, Ticlopidine, Cilostazol, Dipyridamole, Heparin, Dalteparin, Enoxaparin and Warfarin) can be enrolled, but major bleeding events will be captured. Patients on Warfarin will need frequent monitoring of their coagulation time to adjust Warfarin dosage.",{"count":447,"type":21},150,[85],"Currently, the standard of care treatment for newly diagnosed, inoperable stage III non-small cell lung cancer is radiotherapy (RT) with concurrent chemotherapy, followed by immune checkpoint inhibitors (ICI). RT is a highly effect local treatment. However, high doses of radiation used in curative settings can cause adverse side effects. The most common RT side effect in lung cancer is Radiation Induced Lung Injury (RILI), which can manifest as pneumonitis and\u002For pulmonary fibrosis. Lung injury can negatively impact patients' well-being and quality of life, and may lead to increased mortality. Risk of lung injury is particularly increased when patients are treated with a combination of treatments (i.e., RT, chemotherapy, and ICI). The drug Pentoxifylline (in combination with α-Tocopherol (Vitamin E)) has been shown to prevent\u002Falter the progression of lung injury and there is a growing body of evidence to support the safety and efficacy of phosphodiesterase inhibitors in cancer treatment. The proposed study aims to determine if the addition of Pentoxifylline, given in combination with α-Tocopherol (Vitamin E), to standard of care treatment will reduce side effects related to lung injury and improve quality of life in this study population.",[451,452],"Non-Small Cell Lung Cancer","Radiation Induced Lung Injury (RILI)",[444,452,451,454,455],"Pentoxifylline","α-Tocopherol (Vitamin E)",{"date":310,"type":37},{"date":458,"type":37},"2026-06-15",{"date":460,"type":21},"2032-11-30",{"name":43,"class":44},{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":4,"eligibilityCriteria":468,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":469,"targetDuration":4,"studyType":22,"phases":470,"briefSummary":471,"conditions":472,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":481,"leadSponsor":483,"locationsCount":45},"100642722","phase-2-capecitabine-in-erher2-negative-breast-cancer-100642722","NCT07631052","Capecitabine in ER+\u002FHER2-negative Breast Cancer","Capecitabine for Targeted Eradication of aRising ctDNA Molecular Residual Disease in ER+\u002FHER2-negative Breast Cancer","Inclusion Criteria:\n\n* Male or female patients ≥ 18 years of age with histologically confirmed (by local assessment with ASCO\u002FCAP criteria), resected ER-positive\u002FHER2-negative stage I-III breast cancer\n* Evidence of MRD (positive test by the Pathlight assay) despite standard adjuvant therapy\n* No contraindications to capecitabine (including absence of DPYD variants that in the opinion of the investigator are a contraindication to metronomic capecitabine)\n* No clinical or radiographic evidence of recurrent or metastatic disease\n* Previous Therapy requirements: (i) Received at least 24 months of adjuvant endocrine therapy, including 6 months of an aromatase inhibitor and (i) Received at least 12 months of adjuvant CDK4\u002F6i if indicated, unless not tolerated or declined\n* ECOG performance status of 0-1.\n* Patient must have adequate organ function as determined by the following:\n\n  a. Renal function:\n* Serum creatinine \\\u003C 1.5 x ULN (upper limit of normal range) or a calculated creatinine clearance of \\> 50mL\u002Fmin using the Cockcroft-Gault formula\n\n  b. Bone marrow function (without hematopoietic growth factors or transfusion):\n* Absolute neutrophil count (ANC) \\> 1.0 x 109\u002FL\n* Hemoglobin \\> 90 g\u002FL or \\> 9g\u002FdL\n* Platelets \\> 75 x 109\u002FL\n\n  c. Liver function:\n* Total bilirubin ≤ 1.5 × ULN and \\\u003C 35 uMol\u002FL; OR total bilirubin \\>1.5 × ULN with indirect bilirubin \\\u003C 1.5 × ULN.\n* Aspartate aminotransferase (AST\u002FSGOT) and alanine aminotransferase (ALT\u002FSGPT) \\\u003C 2.5 x ULN.\n* Female participants of childbearing potential must have a negative serum β-HCG test result at enrolment.\n* Female participants of childbearing potential must agree to use methods of contraception that are highly effective.\n* Male participants must agree to use methods of contraception that are highly effective.\n* The participant is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.\n* Signed written and voluntary informed consent.\n\nExclusion Criteria:\n\n* Prior therapy with capecitabine.\n* Previous or concurrent malignancy within 3 years of study entry, with the following exceptions: adequately treated basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in-situ of the cervix, or other non-invasive or indolent malignancy; other solid tumors treated curatively without evidence of recurrence for at least 3 years prior to study entry.\n* Impaired cardiovascular function or clinically significant cardiovascular diseases, including any of the following:\n\n  1. History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) \\\u003C6 months prior to screening,\n  2. Symptomatic chronic heart failure (e.g., New York Heart Association Class ≥ 2), history or current evidence of clinically significant cardiac arrhythmia and\u002For conduction abnormality \\\u003C6 months prior to screening except atrial fibrillation and paroxysmal supraventricular tachycardia.\n  3. Uncontrolled hypertension defined as persistent elevation of systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100mmHg, despite current therapy.\n* Known positive serology for HIV (Human immunodeficiency virus) that is not currently controlled with antiretroviral therapy.\n* Has a known history of or is positive for active hepatitis B or hepatitis C unless adequate viral suppression is achieved. Participants who have had definitive treatment for HCV are permitted if HCV RNA is undetectable at Screening Visit.\n* Impaired gastrointestinal function or disease that may significantly alter the absorption of capecitabine.\n* Medical, psychiatric, cognitive, or other conditions that may compromise the patient's ability to understand the patient information, give informed consent, comply with the study protocol, or complete the study.",{"count":176,"type":21},[85],"This is a Phase 2 study for patients with resected Stage I-III HR+\u002FHER2-negative breast cancer with detected molecular residual disease (MRD+) following standard neo\u002Fadjuvant and locoregional therapy delivered with curative intent. In this study participants will be treated with capecitabine. Capecitabine will be administered orally at a dose of 500 mg 3 times daily for up to 12 months, or until the time of clinical recurrence, discontinuation due to toxicity, or withdrawal of consent. This study will have two stages, stage 1 would enroll up to 8 participants to clear the Minimal Residual Disease (MRD) and Stage 2 will enroll up to 5 participants. The purpose of this study is to determine if this study population would have a better outcome from receiving capecitabine rather than having no change in treatment if MRD is detected.",[473,474,475,476],"ER-positive, HER2-negative Breast Cancer","Breast Cancer Stage I","Breast Cancer Stage II","Breast Cancer Stage III","2026-06-09",{"date":479,"type":37},"2026-06-11",{"date":110,"type":21},{"date":482,"type":21},"2029-08-01",{"name":43,"class":44},{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":490,"eligibilityCriteria":491,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":492,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":494,"conditions":495,"keywords":497,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":503,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":508,"locationsCount":45},"100642555","shoulder-ra-survey-study-100642555","NCT07641842","Shoulder RA Survey Study","Patient Experience of Benefits and Limitations of Single Injection Peripheral Nerve Block for Shoulder Surgery: A Cross-sectional Survey","RA","Inclusion Criteria:\n\nParticipants must meet all the following inclusion criteria to be eligible for the study:\n\n1. Patients receiving a single-injection PNB for outpatient arthroscopic shoulder surgery at TWH and WCH\n2. Age ≥18 years\n3. Able to communicate in English\n\nExclusion Criteria:\n\n1. Cognitive impairment (inability to consent to participate in study)\n2. Refusal to participate in study\n3. Patients with primary block failure defined as those without a detectable sensory or motor block (determined by inability to abduct the arm and numbness or loss of sensation to pinprick over lateral shoulder\u002Fdeltoid muscle, C5 dermatome)",{"count":493,"type":21},140,"The purpose of this study, called a cross-sectional survey, is to interview patients on their experiences of pain and recovery following keyhole shoulder surgery, after receiving a single shot nerve block in addition to a general anesthetic. The researchers would like to explore patients' experiences to see if there are groups of patients who may benefit from insertion of a nerve catheter as compared to a single shot nerve block injection for keyhole shoulder surgery.",[496],"Nerve Block",[498,499,500,501,502],"Nerve block","Nerve catheter block","Shoulder Arthroscopic Surgery","Survey","Continuous nerve block catheter infusion",{"date":479,"type":37},{"date":505,"type":21},"2026-05-15",{"date":507,"type":21},"2026-12-31",{"name":43,"class":44},{"id":510,"slug":511,"hasResults":12,"nctId":512,"briefTitle":513,"officialTitle":513,"acronym":514,"eligibilityCriteria":515,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":516,"targetDuration":4,"studyType":22,"phases":517,"briefSummary":518,"conditions":519,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":521,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":526,"locationsCount":45},"100632112","fecal-microbiota-transplantation-in-patients-undergoing-chimeric-antigen-receptor-t-cell-therapy-and-allogeneic-stem-cell-transplant-a-pilot-study-100632112","NCT07509450","Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cell Transplant: A Pilot Study","FMT","Inclusion Criteria:\n\n1. Men and women ≥ 18 years of age\n2. Diagnosis of the following:\n\n   1. Indolent or aggressive B-cell lymphoma eligible for standard or care CAR-T therapy (Cohort A), or\n   2. Patients with AML or high risk MDS with indication to undergo reduced-intensity conditioning alloSCT, with an available matched related, unrelated, or haploidentical donor (Cohort B)\n3. ECOG 0-1\n4. Adequate marrow function defined by:\n\n   1. Hemoglobin \\>80 g\u002FL without transfusion dependence within the last 7 days\n   2. Platelet count \\>20 x 109\u002FL without transfusion dependence within the last 7 days\n   3. Neutrophil count \\>1.0 x 109\u002FL without growth factor support within the last 7 days\n5. Adequate liver function as indicated by aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x the institutional upper limits of normal (ULNs) value; serum total bilirubin \\\u003C 1.5 x ULN (unless documented Gilbert's syndrome)\n6. Adequate renal function as defined as creatinine clearance ≥ 30 mL\u002Fmin directly measured with a 24-hour urine collection or calculated according to the modified formula of Cockcroft-Gault equation or Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) calculation\n7. Life expectancy \\>6 months\n8. Women of childbearing potential (WOCBP) who are sexually active must use highly effective methods of contraception during treatment and up to 6 months after the last dose of protocol therapy. Men who are sexually active must use highly effective methods of contraception during treatment and up to 6 months after the last dose of protocol therapy. Men require an agreement to remain abstinent (ie, refrain from heterosexual intercourse) or use a condom, and an agreement to refrain from donating sperm. Periodic abstinence and withdrawal are not acceptable methods of contraception. Fertility preservation options should be discussed. Examples of highly effective contraceptive methods include an agreement to remain abstinent (ie, refrain from heterosexual intercourse), bilateral tubal ligation, male sterilization, established proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.\n9. Willing and able to participate in all required evaluations and procedures in this study.\n10. Ability to understand and the willingness to sign a written informed consent.\n\nExclusion Criteria:\n\n1. For patients undergoing alloSCT (Cohort B): plan to undergo myeloablative conditioning\n2. Use of investigational agents within the last 4 weeks before enrollment.\n3. Active or uncontrolled infection\n4. Autoimmune disorder currently being treated with disease-modifying therapy or with \\>10mg\u002Fday prednisone\n5. Inflammatory bowel disease\n6. History of intestinal perforation\n7. Gastrointestinal surgical procedure within the past 4 weeks before enrollment\n8. Pregnant or breast-feeding patients\n9. HIV infection with detectable viral load or CD4 count \\\u003C200\n10. Serologic status reflecting active hepatitis B or C infection as follows:\n\n    1. Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with detectable hepatitis B virus (HBV) DNA. (Note, patients with undetectable HBV DNA are permitted to enroll if they are on Hepatitis B suppressive therapy)\n    2. Patients with presence of hepatitis C virus (HCV) antibody and HCV RNA detectable\n11. History of infection or known colonization with antibiotic resistant organism in the last two years before enrollment (including ESBL, MRSA, VISA, VRSA, VRE, CPE)\n12. Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in the study",{"count":128,"type":21},[24],"This is a single site pilot trial will evaluate the feasibility and safety of fecal microbiota transplantation (FMT) in patients with B-cell lymphoma who are undergoing CAR-T or in patients with moderate to high-risk acute myeloid leukemia or myelodysplastic syndrome who are undergoing allogeneic stem cell transplantation.",[520],"Lymphoma Receiving CAR-T Therapy",{"date":479,"type":37},{"date":523,"type":37},"2026-06-02",{"date":525,"type":21},"2029-06-02",{"name":43,"class":44},{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":533,"eligibilityCriteria":534,"healthyVolunteers":12,"sex":397,"minAge":53,"maxAge":4,"enrollmentInfo":535,"targetDuration":4,"studyType":22,"phases":537,"briefSummary":538,"conditions":539,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":541,"startDateStruct":543,"completionDateStruct":544,"leadSponsor":546,"locationsCount":45},"100634147","phase-2-clinical-trial-to-observe-the-effects-of-tamoxifen-on-testosterone-recovery-in-medically-castrated-prostate-cancer-patients-100634147","NCT07535905","Clinical Trial to Observe the Effects of Tamoxifen on Testosterone Recovery in Medically Castrated Prostate Cancer Patients","Phase II Controlled Clinical Trial to Test Efficacy and Observe Longitudinal Effects of Tamoxifen for Testosterone Recovery in Medically Castrated Prostate Cancer Patients","REVIVE","Inclusion Criteria:\n\n* At least 18 years of age;\n* Ability to understand the purposes and risks of the trial and has signed a written informed consent form. Have a diagnosis of prostate cancer;\n* Patient received ADT for a duration of either 6 or 18-36 months as part of the curative intent treatment. Curative intent prostate cancer patients who completed ADT and have had no further ADT for the length of the last ADT injection depot formulation (e.g., if the last ADT injection depot formulation is for 3 months, the patient must have no ADT for 3 months after last injection)\n* Have effectively castrated testosterone (\\\u003C 1.7 nmol\u002FL \\[50 ng\u002FdL\\]) within 6 weeks of enrollment;\n* ECOG Performance status 0-2\n\nExclusion Criteria:\n\n* Harbouring certain CYP2D6 alleles (i.e. CYP2D6\\*4) or from the chronic use of a CYP2D6 inhibitor(s);\n* History of blood clots (venous thromboembolism or pulmonary embolism);\n* History of stroke or transient ischemic attack (TIA);\n* Reduced liver function within last 120 days prior to enrolment, defined as follows:\n\n  1. Total Bilirubin: 1.5 \\> upper limit of normal (ULN) (For Gilbert's syndrome, if total bilirubin is \\\u003C1.5 x ULN, measure direct and indirect bilirubin. If direct bilirubin is greater than 1.5 x ULN, participant is ineligible;\n  2. AST(SGOT) and ALT(SGPT): \\> 2.5x ULN;\n  3. Or other liver disease as deemed ineligible by the investigator\n* Baseline QT\u002FQTc \\> 500ms;\n* Active therapy with selective serotonin reuptake inhibitor (SSRI) antidepressants (e.g. paroxetine, a known CYP2D6 inhibitor);\n* Active therapy with coumarin-type anticoagulants;\n* Active therapy with cytotoxic agents;\n* Active therapy with aromatase inhibitors;\n* Other invasive malignancy within the last 5 years, other than squamous or basal cell carcinoma of the skin;\n* Treatment with a non-approved or experimental drug during the 3 months before informed consent;\n* Patients known to have one of the following hereditary illnesses; galactose- intolerance, Lapp lactase deficiency or glucose-galactose malabsorption;\n* Any other significant concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the participant in this trial;",{"count":536,"type":21},96,[85],"Androgen deprivation therapy (ADT) is a cornerstone therapy in the treatment of curable prostate cancer (PCa). However, ADT often leads to a protracted testosterone recovery period in most men or absence of complete recovery in 10-25% of cases. The hypogonadal state has significant psychosocial and physical side effects. Therefore, limiting ADT effect's duration beyond the prescribed castration period is very compelling to patients and providers alike.\n\nTamoxifen, a well-established selective estrogen receptor modulator, offers a novel and cost-effective approach to accelerate testosterone recovery in men with secondary hypogonadism. This project addresses a critical gap in global cancer care by evaluating Tamoxifen as a viable solution for reducing the burden of delayed testosterone recovery and its associated side effects, particularly in resource-limited settings.",[540,405],"Hypogonadism",{"date":542,"type":37},"2026-06-10",{"date":313,"type":21},{"date":545,"type":21},"2030-10",{"name":43,"class":44},{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":4,"eligibilityCriteria":553,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":554,"targetDuration":4,"studyType":22,"phases":555,"briefSummary":556,"conditions":557,"keywords":560,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":562,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":568,"locationsCount":45},"100628051","phase-1-study-of-the-safety-and-usefulness-of-liposomal-curcumin-in-multiple-myeloma-100628051","NCT07456605","Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma","Phase I Study of Safety and Efficacy of Liposomal Curcumin in Relapsed Refractory Multiple Myeloma","Inclusion Criteria:\n\n* Must be able to understand and voluntarily sign an informed consent form (ICF).\n* Must be ≥ 18 years of age at the time of signing the ICF\n* Must be able to adhere to the study visit schedule and other protocol requirements.\n* Relapsed and\u002For refractory MM with:\n* Documented evidence of progressive disease (PD) after achieving at least stable disease (SD) for ≥ 1 cycle during a previous MM treatment (i.e., relapsed MM). OR Disease progression during or within 60 days from the end of the most recent MM treatment (i.e., refractory MM).\n* Previously undergone treatment with at least one immunomodulatory drug (lenalidomide or pomalidomide), one proteasome inhibitor (bortezomib, ixazomib, carfilzomib) and one anti-CD38 drug (daratumumab or isatuximab). These drugs could have been used in separate regimens or in combination.\n* No effective standard of care options available\n* Patients with a history of autologous stem cell transplant are eligible for study participation provided the following eligibility criteria are met:\n* transplant was \\> 12 weeks prior to study enrolment\n* no active infection\n* Patients with measurable disease defined as at least one of the following (these baseline laboratory studies for determining eligibility must be obtained within 28 days prior to start of study drug):\n* Serum M-protein ≥ 0.5 g\u002Fdl (≥ 5 g\u002Fl)\n* Urine M-protein ≥ 200 mg\u002F24 h\n* Serum free light chains (FLC) assay: Involved FLC level ≥ 10 mg\u002Fdl (≥ 100 mg\u002Fl) and an abnormal serum free light chain ratio (\\\u003C 0.26 or \\> 1.65)\n* If the serum protein electrophoresis is unreliable for routine M-protein measurement, quantitative immunoglobulin levels on nephelometry or turbidometry will be followed.\n* Must have Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 2.\n* Females of child-bearing potential (FCBP) must have a negative serum pregnancy test and must either commit to continued abstinence from heterosexual intercourse or must abide by birth control requirements as described.\n* Men with a female partner of childbearing potential must agree to use effective contraception from the time of first dose of study until 90 days after the last dose of study treatment to allow for clearance of any altered sperm.\n* Able to take oral medications\n* All prior treatment-related toxicities (defined by National Cancer Institute- Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 5) must be ≤Grade 1 at the time of enrollment except for alopecia or be deemed to be irreversible (for example, steroid induced cataracts or peripheral neuropathy).\n* The following laboratory results must be met within 7 days of first study drug administration:\n* Absolute neutrophil count (ANC) \\>1000 cells\u002FdL (1.0 x 10\\^9\u002FL). Growth factors cannot be given within 7 days of study drug administration.\n* Serum AST and ALT ≤ 3 x upper limit of normal (ULN).\n* Creatinine clearance ≥ 20 mL\u002Fmin either directly measured via 24-hour urine collection or calculated using Cockroft-Gault\n* Platelet count ≥ 50 x 109\u002FL. For patients with \\> 50% myeloma involvement in the marrow, a platelet count of ≥30 x 109\u002FL is allowed. Patients may not have received a platelet transfusion within 72 hours prior to the platelet count used for eligibility\n* Hemoglobin ≥ 80 g\u002FL. Patients may receive red blood cell (RBC) transfusions in accordance with institutional guidelines to meet this criterion. Patients may not have received a red blood cell (RBC) transfusion within 72 hours prior to the hemoglobin result used for eligibility; use of growth factors is allowed.\n* Total bilirubin ≤ 1.5 x ULN, unless known to have Gilbert's disease.\n* Albumin ≥ 2.0 g\u002FdL (20 g\u002FL).\n* Calcium \\\u003C1.2xULN.\n\nExclusion Criteria:\n\n* Known history of clinically active amyloidosis, POEMS syndrome, or patients with plasma cell leukemia defined as circulating plasma cell count exceeding 500\u002FuL or 5% of the peripheral blood white cells at the time of screening\n* Any serious and\u002For unstable pre-existing medical, psychiatric disorder, or other conditions (including lab abnormalities) that could interfere with patient's safety, obtaining informed consent or compliance to the study procedures.\n* Pregnant or lactating females.\n* Patients with previous or concurrent malignancies are allowed only if the second tumor is not contributing to the patient's illness. The patient must not be receiving active therapy, other than hormonal therapy for this disease and the disease must be considered medically stable for at least 2 years. The following are allowed:\n* Adequately treated in situ carcinoma of the cervix uteri or the breast;\n* Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;\n* In situ malignancy;\n* Prostate cancer Gleason grade 6 or lower AND with stable Prostate Specific Antigen levels off treatment;\n* Previous malignancy with no evidence of disease confirmed and surgically resected (or treated with other modalities) with curative intent and unlikely to impact survival during the duration of the study.\n* Evidence of cardiovascular risk including any of the following:\n* QTc interval ≥ 470 msecs.\n* Evidence of current clinically significant uncontrolled arrhythmias; including clinically significant ECG abnormalities; including 2nd degree (Type II) or 3rd degree atrioventricular (AV) block.\n* History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within six months of Screening.\n* Class III or IV heart failure as defined by the New York Heart Association functional classification system\n* Uncontrolled hypertension\n* Ejection fraction \\\u003C40% as determined by echocardiogram\n* Active human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Presence of hepatitis B surface antigen (HBsAg) or positive HBV PCR test at screening or within 3 months prior to first dose of study treatment. Participants with positive hepatitis B core antibody (HBcAb) can be enrolled, only if confirmatory negative Hepatitis B DNA is obtained AND patient is on hepatitis B prophylaxis (e.g. tenofovir or entecavir) before first dose of study drugs. Presence of isolated Hep B surface antibody (HBsAb) indicating previous vaccination will not exclude a participant. Positive hepatitis C antibody test result or positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study treatment. Note: Participants with positive Hepatitis C antibody due to prior resolved disease can be enrolled, only if a confirmatory negative Hepatitis C RNA test is obtained. Hepatitis RNA testing is optional and participants with negative Hepatitis C antibody test are not required to also undergo Hepatitis C RNA testing. Patients with HIV with detectable viral load or with AIDS-defining features or illnesses will be excluded.\n* Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones, liver metastases or otherwise stable chronic liver disease per investigator's assessment).\n* Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, hepatic, renal or cardiac disease).\n* Current or past history of clinically significant CNS disease, such as stroke, epilepsy, CNS vasculitis, neurodegenerative disease, or CNS involvement by MM\n* Note that patients with a history of stroke who have not experienced a stroke or transient ischemic attack in the past 2 years and have no residual neurologic deficits as judged by the investigator are allowed.\n* Note that patients with a history of epilepsy who have had no seizures in the past 2 years while not receiving any anti-epileptic medications are allowed.\n* Known active infection requiring treatment.\n* Receiving systemic immunosuppressive medications (including, but not limited to, azathioprine, methotrexate, and anti-tumor necrosis factor agents), with the exception of corticosteroid treatment \\\u003C10mg\u002Fday prednisone or equivalent within 2 weeks. Inhaled corticosteroids for respiratory diseases are allowed.\n* Evidence of active mucosal or internal bleeding.\n* Significant urinary outflow obstruction\n* Radiotherapy or systemic therapy (standard or biologic anticancer agent) within 14 days of initiation of study drug treatment.\n* Use of an investigational drug within 21 days or five half-lives, whichever is shorter, preceding the first dose of study drug.\n* Major surgery within 28 days\n* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to liposomal curcumin.",{"count":128,"type":21},[84],"The purpose of this study is to test the safety of in investigational drug called Liposomal curcumin (LipoCurc) and to find the highest dose that can be given without causing very severe side effects.\n\nTo do this participants are given LipoCurc and are watched very closely to see what side effects they have and to make sure the side effects are not severe. If the side effects are not severe, then new participants will be given a higher dose of LipoCurc. Participants joining this study later on will get higher doses of LipoCurc than participants who join earlier. This will continue until a dose is found that causes severe but temporary side effects. Doses higher than that will not be given.",[558,559],"Multiple Myeloma Refractory","Multiple Myeloma in Relapse",[561],"Liposomal Curcumin",{"date":563,"type":37},"2026-06-12",{"date":565,"type":37},"2026-02-27",{"date":567,"type":21},"2028-03-02",{"name":43,"class":44},{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":575,"eligibilityCriteria":576,"healthyVolunteers":12,"sex":397,"minAge":577,"maxAge":4,"enrollmentInfo":578,"targetDuration":4,"studyType":22,"phases":579,"briefSummary":580,"conditions":581,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":582,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":45},"100550774","a-pan-canadian-investigator-initiated-clinical-trial-with-focal-ire-directed-to-intermediate-risk-prostate-cancer-100550774","NCT06451445","A Pan-Canadian, Investigator Initiated Clinical Trial With Focal IRE Directed to Intermediate-Risk Prostate Cancer","A Pan-Canadian, Investigator Initiated Clinical Trial With Focal IRE Directed to Intermediate-Risk Prostate Cancer: The WIRED Study","WIRED","Inclusion Criteria:\n\n1. Is greater than 50 years of age\n2. Has at least a 10-year life expectancy\n3. Has histologically confirmed organ-confined prostate cancer, clinical stage ≤ T2c\n4. Has a PSA ≤ 15 ng\u002FmL or PSA density \\\u003C 0.15 ng\u002FmL2 if PSA is \\> 15 ng\u002FmL\n5. Has Gleason score 3+4 or 4+3\n6. Has no evidence of extraprostatic extension by mpMRI\n7. Has no evidence of seminal vesicle invasion by mpMRI\n8. Physician is able to visualize prostate gland adequately on transrectal ultrasound imaging during qualifying biopsy\n9. Has a transperineal or transrectal targeted prostate biopsy of MRI-visible lesions, plus 10-14 core systematic biopsy confirming Gleason = 7 in MRI target and absence of Gleason ≥ 7 outside target\n10. A visible lesion on mpMRI that is accessible to Irreversible Electroporation (IRE) treatment \\[Note: prostate cancer detected via systematic standard biopsy outside of the adjacent sextant location of the MRI visible lesion will meet entry criterion provided the positive core is Gleason 6; has fewer than 3 prostate biopsy fragments\u002Fcores positive\\]\n11. Willing and able to sign a written informed consent form.\n12. Understands and accepts the obligation and is logistically able to present for all scheduled follow-up visits\n\nExclusion Criteria:\n\n1. Has known hypersensitivity to pancuronium bromide, atricurium or cisatricurium\n2. Is unfit for anesthesia or has a contraindication for agents listed for paralysis\n3. Has an active urinary tract infection (UTI)\n4. Has a history of bladder neck contracture\n5. Is interested in future fertility\n6. Has a history (within 3 years) of inflammatory bowel disease\n7. Has a concurrent major debilitating illness\n8. Had active treatment for a malignancy within 3 years, including malignant melanoma, except for prostate cancer or other types of skin cancer (Note: subjects with untreated active concomitant cancers are excluded, only subjects deemed to be in remission by their cancer care provider for at least three years are eligible)\n9. Has any active implanted electronic device (e.g., pacemaker)\n10. Is unable or unwilling to catheterize\n11. Has had any prior or current prostate cancer therapy, including:\n\n    1. Biologic therapy for prostate cancer\n    2. Chemotherapy for prostate cancer\n    3. Hormonal therapy for prostate cancer within three months of procedure\n    4. Radiotherapy for prostate cancer\n    5. Surgery for prostate cancer\n12. Has had prior prostate stricture surgery, urethral stent or prostatic implants\n13. Has had prior major rectal surgery (except hemorrhoids)\n14. Is unfit for pelvic MRI scanning (e.g., severe claustrophobia, permanent cardiac pacemaker, metallic implants that are likely to contribute significant image artifacts, allergy or contraindication to gadolinium (to enhance MRI)","50 Years",{"count":328,"type":21},[24],"The goal of this clinical trial is to investigate the safety and efficacy of Irreversible Electroporation (IRE) using NanoKnife technology in patients with intermediate-risk prostate cancer. This patient population was chosen because they would otherwise be treated with conventional therapies with high side effects. The main questions it aims to answer are:\n\n1. Is the NanoKnife system is effective at damaging prostate tumour cells, and killing the cancer?\n2. Are there any safety concerns with the procedure, or major side effects caused by the treatment?\n\nParticipants will undergo IRE treatment with the NanoKnife system, and then complete follow-up appointments for 12-months after the procedure.",[405],{"date":479,"type":37},{"date":584,"type":37},"2024-05-16",{"date":586,"type":21},"2033-05",{"name":43,"class":44},""]